| Q35335708 | A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: study rationale and design |
| Q41877489 | Acute effects of nonexcitatory electrical stimulation during systole in isolated cardiac myocytes and perfused heart. |
| Q37407710 | Biventricular and novel pacing mechanisms in heart failure |
| Q41775044 | Ca(2+)-binding proteins in dogs with heart failure: effects of cardiac contractility modulation electrical signals |
| Q59697872 | Cardiac Contractility Modulation in a Model of Repaired Tetralogy of Fallot: A Sheep Model |
| Q34284212 | Cardiac contractility modulation for heart failure: a meta-analysis of randomized controlled trials |
| Q91084624 | Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction |
| Q38101970 | Cardiac contractility modulation in patients with advanced heart failure |
| Q37867850 | Cardiac contractility modulation in the treatment of heart failure: initial results and unanswered questions |
| Q37690133 | Cardiac contractility modulation increases action potential duration dispersion and decreases ventricular fibrillation threshold via β1-adrenoceptor activation in the crystalloid perfused normal rabbit heart |
| Q46952259 | Cardiac contractility modulation therapy in advanced systolic heart failure |
| Q37371212 | Cardiac contractility modulation: a novel approach for the treatment of heart failure |
| Q34413880 | Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation |
| Q93370282 | Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond |
| Q34281396 | Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure |
| Q104067233 | Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function |
| Q47735989 | Contribution of sodium channel neuronal isoform Nav1.1 to late sodium current in ventricular myocytes from failing hearts |
| Q84083761 | Effects of electric stimulations applied during absolute refractory period on cardiac function of rabbits with heart failure |
| Q37812008 | Electrical modalities beyond pacing for the treatment of heart failure |
| Q50968804 | First use of cardiac contractility modulation (CCM) in a patient failing CRT therapy: clinical and technical aspects of combined therapies. |
| Q34899041 | Improvement in glycemic control by gastric electrical stimulation (TANTALUS) in overweight subjects with type 2 diabetes |
| Q34167917 | Improving left ventricular contraction by stimulation during the absolute refractory period. Cardiac contractility modulation |
| Q36025342 | Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol |
| Q37609687 | Large animal models of heart failure: a critical link in the translation of basic science to clinical practice |
| Q34784692 | Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs |
| Q34387086 | New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association |
| Q38893579 | Post-extrasystolic Potentiation: Link between Ca(2+) Homeostasis and Heart Failure? |
| Q37038947 | Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure |
| Q37740801 | Review article: the new concept of interventional heart failure therapy--part 1: electrical therapy, treatment of CAD, fluid removal, and ventricular support |
| Q37089726 | Tackling heart failure in the twenty-first century |
| Q35223644 | The acute inotropic effects of cardiac contractility modulation (CCM) are associated with action potential duration shortening and mediated by β1-adrenoceptor signalling |
| Q34232612 | The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure. |
| Q64092741 | Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction |
| Q34215896 | Treating congestive heart failure with cardiac contractility modulation (CCM) : possibilities and study overview |
| Q52912486 | [Improving left ventricular contractility by stimulation during the absolute refractory period--cardiac contractility modulation (CCM)]. |
| Q83250057 | [Progress in cardiac pacing] |